New Insulins,Biosimilars,and Insulin Therapy

Hövelmann U , Brøndsted L , Kristensen NR , et al. Insulin Icodec: an insulin analog suited for once-weekly dosing in type 2 diabetes. Diabetes, 2020; 69: 237-OR.

Rosenstock J , Kjaersgaard MIS , Moller D , Voigt Hansen M , Goldenberg R . Once-weekly basal insulin Icodec offers comparable efficacy and safety vs. once-daily insulin glargine U100 in insulin-naïve patients with T2D inadequately controlled on OADs. Diabetes, 2020; 69: 238-OR.

DeVries JH. OP—Weekly basal insulin—The wave of the future? ADA 80th Annual Scientific Sessions, virtual meeting. Plan.core-apps.com/tristar_ada20/event/20ebfeed4106d06a95df4f665fad8271.

Rosenstock J , Cheng A , Ritzel R , et al. More similarities than differences testing insulin glargine 300 units/mL versus insulin degludec 100 units/mL in insulin-naïve type 2 diabetes: the randomized head-to-head BRIGHT trial. Diabetes Care, 2018; 41: 2147–2154.

Del Prato S . How conclusive is the CONCLUDE trial?. Diabetologia, 2020; 63: 692–697.

Philis-Tsimikas A , Stratton I , Nørgård Troelsen L , et al. Efficacy and safety of degludec compared to glargine 300 Units/mL in insulin-experienced patients with type 2 diabetes: trial protocol amendment (NCT03078478). J Diabetes Sci Technol, 2019; 13: 498–506.

Danne T , Matsuhisa M , Sussebach C , et al. Lower risk for severe hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL in participants with type 1 diabetes: meta-analysis of 6-month phase 3 clinical trials. Diabetes Obes Metab 2020 Jun 9. DOI: 10.1111/dom.14109 [Epub ahead of print].

Battelino T , Bosnyak Z , Danne T , et al. InRange: comparison of the second-generation basal insulin analogues glargine 300 U/mL and degludec 100 U/mL in persons with type 1 diabetes using continuous glucose monitoring—study design. Diabetes Ther, 2020; 11: 1017–1027.

Fath M , Danne T , Biester T , et al. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes, 2017; 18: 903–910.

Danne T , Becker RH , Heise T , et al. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care, 2005; 28: 2100–2105.

Cengiz E , Tamborlane WV , Martin-Fredericksen M , Dziura J , Weinzimer SA . Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes. Diabetes Care, 2010; 33: 1009–1012.

Haahr H , Pieber TR , Mathieu C , et al. Clinical pharmacology of fast-acting insulin aspart versus insulin aspart measured as free or total insulin aspart and the relation to anti-insulin aspart antibody levels in subjects with type 1 diabetes mellitus. Clin Pharmacokinet, 2019; 58: 639–649.

Danne T , Heinemann L , Bolinder J . New insulins, biosimilars, and insulin therapy. Diabetes Technol Ther, 2019; 21(S1): S57–S78.

Swan KL , Dziura JD , Steil GM , et al. Effect of age of infusion site and type of rapid-acting analog on pharmaco-dynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy. Diabetes Care, 2009; 32: 240–244.

Clausen TS , Kaastrup P , Stallknecht B . Effect of insulin catheter wear-time on subcutaneous adipose tissue blood flow and insulin absorption in humans. Diabetes Technol Ther, 2009; 11: 575–580.

Klonoff DC , Evans ML , Lane W , et al. A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5). Diabetes Obes Metab, 2019; 21: 961–967.

Evans M , Ceriello A , Danne T , et al. Use of fast-acting insulin aspart in insulin pump therapy in clinical practice. Diabetes Obes Metab, 2019; 21: 2039–2047.

Breton MD , Kanapka LG , Beck RW , et al., for the iDCL Trial Research Group. A randomized trial of closed-loop control in children with type 1 diabetes. N Engl J Med, 2020; 383: 836–845.

Shingaki T , Taki K , Koyanagi M , et al. Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study. Curr Med Res Opin, 2020; 36: 947–958.

Luo J , Kesselheim AS , Sarpatwari A . Insulin access and affordability in the USA: anticipating the first interchangeable insulin product. Lancet Diabetes Endocrinol, 2020; 8: 360–362.

Socal MPG , Garrett JB , Tayler WB , Anderson GF . Naming convention, interchangeablility, and patient interest in biosimilar. Diabetes Spectrum, 2020; 33: 273–279.

Socal MP , Greene JA . Interchangeable insulins—new pathways for safe, effective, affordable diabetes therapy. N Engl J Med, 2020; 382: 981–983.

Carter AW , Heinemann L . If PBMs guard access to drugs, then quis custodiet ipsos custodies?. (Who will guard the guardians?) J Diabetes Sci Technol , 2016; 10: 1406–1410.

Karonova TL , Mosikian AA , Mayorov AY , et al. Safety and efficacy of GP40061 compared with originator insulin glargine (Lantus^®): a randomized open-label clinical trial. J Comp Eff Res, 2020; 9: 263–273.

Korn M . Wohlfart P, Gossas T, et al. Comparison of metabolic and mitogenic response in vitro of the rapid-acting insulin lispro product SAR342434, and US- and EU-approved Humalog^® . Regul Toxicol Pharmacol, 2019; 109: 104497.

Heinemann L , Owens D . Biosimilar insulin and insulin antibodies. J Diabetes Sci Technol, 2013; 7: 806–807.

Carter AW , Heinemann L , Klonoff DC . Quality control of insulins and biosimilar insulins: what do we know?. J Diabetes Sci Technol, 2016; 10: 811–815.

Owens DR , Landgraf W , Schmidt A , Bretzel RG , Kuhlmann MK . The emergence of biosimilar insulin preparations—a cause for concern?. Diabetes Technol Ther, 2012; 14: 989–996.

Lavalle-Gonzalez FJ , Khatami H . The biosimilar insulin landscape: current developments. Postgrad Med, 2014; 126: 81–92.

García-Nares H , Leyva-Carmona MI , Pérez-Xochipa N , Chiquete E . Hypersensitivity reaction to a biosimilar insulin glargine. J Diabete, 2015; 7: 155–157.

Agirrezabal I , Sánchez-Iriso E , Mandar K , Cabasés JM . Real-world budget impact of the adoption of insulin glargine biosimilars in primary care in England (2015–2018). Diabetes Care, 2020; 43: 1767–1773.

Hoy SM . MYL1501D insulin glargine: a review in diabetes mellitus. BioDrugs, 2020; 34: 245–251.